Cite

HARVARD Citation

    Lamers-Karnebeek, F. et al. (2019). Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity. Rheumatology. pp. 427-431. [Online]. 
  
Back to record